Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing proprietary pharmaceuticals that improve the treatment of cancer.

Cantex's pipeline has two product candidates in clinical development (CX-01 and Dicopp®) targeting disease indications (acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and metastatic pancreatic cancer) for which innovative and more effective treatments are greatly needed.

Latest News


Cantex has received FDA Fast Track and Orphan Drug Designation of its lead product candidate, CX-01, in newly diagnosed AML and is planning a Phase 3 clinical study in that indication.

Cantex plans to commence a Phase 2 clinical study of Dicopp® in metastatic pancreatic cancer, in the first half of 2019.

Click here to learn more about the scientific rationale underpinning each of these innovative programs.